Investigating antiviral treatment in COVID-19
When COVID-19 entered the world stage in late 2019, it was clear that this virus could cause severe lung illness. Many people were becoming so breathless they required hospitalisation, supplemental oxygen and ventilation. Human lungs were not coping as they should with this virus.
Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries.
SG016 Trial
Phase 2 double-blind, placebo-controlled trial of inhaled IFN-β , SNG001, in hospitalised COVID-19 patients
Read more about SG016 at clinicaltrials.gov
Access the results of SG016 in the Lancet Respiratory Medicine.
SG018 SPRINTER Trial
Phase 3 double-blind, placebo-controlled, trial of inhaled IFN-β, SNG001, in hospitalised COVID-19 patients
Read more about SG018 at clinicaltrials.gov
Synairgen reported topline results of SPRINTER (SG018) in February 2022, and a more detailed full analysis including post hoc analyses at the ATS International Conference in May 2022.
In September 2022, Synairgen announced positive findings from the analysis of data from 60 and 90-day follow-up visits (Long COVID) from SG018.